Table 1.
Cases used with neuropathological correlation
| Temporal cortex |
Pathology |
Counts |
Braak stage | PMI (h) | Age | ||
|---|---|---|---|---|---|---|---|
| Diffuse plaques | Neuritic plaques | NFT | |||||
| AD | Case 1 | 47 | 15 | 17 | 6 | 3.5 | 87 |
| Case 2 | 34 | 16 | 31 | 6 | 3 | 93 | |
| Case 3 | 50 | 30 | 31 | 6 | 3.33 | 84 | |
| Case 4 | 38 | 23 | 11 | 6 | 2.33 | 75 | |
| Case 5 | 18 | 22 | 35 | 6 | 4.5 | 84 | |
| Case 6 | 50 | 20 | 14 | 6 | 2.75 | 90 | |
| Average | 40 | 21 | 23 | 6.0 | 3.2 | 85.5 | |
| MCI | Case 1 | 7 | 9 | 1 | 3 | 2.45 | 97 |
| Case 2 | 47 | 12 | 0 | 3 | 5 | 91 | |
| Case 3 | 0 | 0 | 0 | 3 | 2.75 | 93 | |
| Case 4 | 50 | 9 | 1 | 4 | 3.5 | 87 | |
| Case 5 | 22 | 14 | 0 | 3 | 2.9 | 82 | |
| Case 6 | 50 | 5 | 5 | 5 | 2 | 99 | |
| Average | 29 | 8 | 1 | 3.5 | 3.1 | 91.5 | |
| Nondemented | Case 1 | 4 | 6 | 0 | 1 | 4 | 91 |
| with SMT | Case 2 | 3 | 0 | 0 | 0 | 3.25 | 92 |
| plaques | Case 3 | 37 | 9 | 0 | 2 | 2.75 | 93 |
| Case 4 | 17 | 2 | 0 | 2 | 2.4 | 87 | |
| Case 5 | 3 | 2 | 0 | 0 | 3.5 | 95 | |
| Average | 13 | 4 | 0 | 1.0 | 3.2 | 91.6 | |
| Nondemented | Case 1 | 0 | 0 | 0 | 2 | 1.66 | 85 |
| without SMT | Case 2 | 0 | 0 | 0 | 1 | 5 | 88 |
| plaques | Case 3 | 0 | 0 | 0 | 1 | 2.25 | 80 |
| Case 4 | 0 | 0 | 0 | 1 | 1.75 | 86 | |
| Case 5 | 0 | 0 | 0 | 2 | 4 | 90 | |
| Case 6 | 0 | 0 | 0 | 1 | 2 | 76 | |
| Average | 0 | 0 | 0 | 1.3 | 2.8 | 84.2 |
Cases used for miRNA microarray involved detailed evaluation, both prior and subsequent to patients' death. Brain samples were obtained immediately subjacent to tissue that was used for detailed neuropathological evaluation. “Pathology counts” represent a quantitation of neuropathological lesions as described in detail previously (Nelson et al., 2007). SMT signifies the superior and middle temporal gyri. Note that, in these areas, there is a graded increase in pathology between the four groups. NFT, Neurofibrillary tangle.